Comparison of intravitreal bevacizumab followed by ranibizumab for the treatment of neovascular age-related macular degeneration

Retina

Volumn 29, Issue 8, 2009, Pages 1067-1073

  Stepien, Kimberly E ^a   Rosenfeld, Philip J ^a   Puliafito, Carmen A ^a   Feuer, William ^a   Shi, Wei ^a   Al Attar, Luma ^a   Dubovy, Sander R ^a   Murray, Timothy G ^a   Davis, Janet L ^a   Lee, Wen Hsiang ^a   Schwartz, Stephen G ^a   Smiddy, William E ^a   Berrocal, Audina M ^a   Flynn, Harry W ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Age related; Bevacizumab (Avastin); Injection; Intravitreal; Macular degeneration; Ranibizumab (Lucentis); Retina; Vascular endothelial growth factor A; Visual acuity

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; TRIAMCINOLONE ACETONIDE; VERTEPORFIN;

ABSENCE OF SIDE EFFECTS; CONTROLLED STUDY; DRUG EFFICACY; FOOD AND DRUG ADMINISTRATION; HUMAN; MAJOR CLINICAL STUDY; PHOTODYNAMIC THERAPY; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SCORING SYSTEM; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL ACUITY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; DRUG ADMINISTRATION SCHEDULE; HUMANS; MACULAR DEGENERATION; RETINAL NEOVASCULARIZATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 70349124649     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181b1bb06     Document Type: Review

References (25)

1. Adamis AP, Shima DT. The role of vascular endothelial growth factor in ocular health and disease. Retina 2005;25: 111-118.
2. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444.
3. Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
4. Moshfeghi AA, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology 2006;113: 2002.e1-e12.
5. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevaci-zumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36:331-335.
6. Yoganathan P, Deramo VA, Lai JC, Tibrewala RK, Fastenberg DM. Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration. Retina 2006;26:994-998.
7. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin(R)): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Oph-thalmol 2008;246:81-87.
8. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006;26:383-390. (Pubitemid 44197628)
9. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovas-cular age-related macular degeneration. Retina 2006;26:495-511.
10. Melamud A, Stinnett S, Fekrat S. Treatment of neovascular age-related macular degeneration with intravitreal bevaci-zumab: efficacy of three consecutive monthly injections. Am J Ophthalmol 2008;146:91-95.
11. Lazic R, Gabric N, Dekaris I, Saric B, Gavric M. Intravitreal bevacizumab (Avastin) in treatment of neovascular age-related macular degeneration. Coll Antropol 2007;31(suppl 1):77-81.
12. Goff MJ, Johnson RN, McDonald HR, Ai E, Jumper JM, Fu A. Intravitreal bevacizumab for previously treated choroidal neo-vascularization from age-related macular degeneration. Retina 2007;27:432-438.
13. Emerson MV, Lauer AK, Flaxel CJ, et al. Intravitreal bevaci-zumab (Avastin) treatment of neovascular age-related macular degeneration. Retina 2007;27:439-444.
14. Costa RA, Jorge R, Calucci D, Cardillo JA, Melo LA Jr, Scott IU. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study. Invest Ophthalmol Vis Sci 2006;47:4569-4578.
15. Cleary CA, Jungkim S, Ravikumar K, Kelliher C, Acheson RW, Hickey-Dwyer M. Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6- and 9-month results. Eye 2008;22:82-86.
16. Chen CY, Wong TY, Heriot WJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study. Am J Ophthalmol 2007;143:510-512.
17. Bhatnagar P, Spaide RF, Takahashi BS, et al. Ranibizumab for treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2007;27:846-850.
18. Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP, Noureddin BN. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006;142:1-9.
19. Bashshur ZF, Haddad ZA, Schakal A, Jaafar RF, Saab M, Noureddin BN. Intravitreal bevacizumab for treatment of neo-vascular age-related macular degeneration: a one-year prospective study. Am J Ophthalmol 2008;145:249-256.
20. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovas-cular age-related macular degeneration. Ophthalmology 2006; 113:363-372.e5.
21. Algvere PV, Steen B, Seregard S, Kvanta A. A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations. Acta Ophthalmol 2008;86:482-489.
22. Aggio FB, Farah ME, Silva WC, Melo GB. Intravitreal bev-acizumab for exudative age-related macular degeneration after multiple treatments. Graefes Arch Clin Exp Ophthalmol 2007; 245:215-220.
23. Steinbrook R. The price of sight-ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med 2006;355:1409-1412.
24. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol 1999;117: 1329-1345.
25. Stewart MW. Predicted biologic activity of intravitreal bev-acizumab. Retina 2007;27:1196-1200.